2seventy bio (TSVT) Competitors $3.11 -0.10 (-3.12%) (As of 09:46 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TSVT vs. RLAY, PRTA, CRGX, CRON, EOLS, RAPP, ESPR, ANAB, CGEM, and DNTHShould you be buying 2seventy bio stock or one of its competitors? The main competitors of 2seventy bio include Relay Therapeutics (RLAY), Prothena (PRTA), CARGO Therapeutics (CRGX), Cronos Group (CRON), Evolus (EOLS), Rapport Therapeutics (RAPP), Esperion Therapeutics (ESPR), AnaptysBio (ANAB), Cullinan Therapeutics (CGEM), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. 2seventy bio vs. Relay Therapeutics Prothena CARGO Therapeutics Cronos Group Evolus Rapport Therapeutics Esperion Therapeutics AnaptysBio Cullinan Therapeutics Dianthus Therapeutics 2seventy bio (NASDAQ:TSVT) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability. Which has more risk and volatility, TSVT or RLAY? 2seventy bio has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Is TSVT or RLAY more profitable? Relay Therapeutics has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. Relay Therapeutics' return on equity of -45.75% beat 2seventy bio's return on equity.Company Net Margins Return on Equity Return on Assets 2seventy bio-207.25% -53.65% -23.67% Relay Therapeutics N/A -45.75%-40.75% Which has higher valuation and earnings, TSVT or RLAY? 2seventy bio has higher revenue and earnings than Relay Therapeutics. 2seventy bio is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio2seventy bio$100.39M1.65-$217.57M-$1.86-1.73Relay Therapeutics$10.01M75.28-$341.97M-$2.61-1.72 Does the MarketBeat Community prefer TSVT or RLAY? Relay Therapeutics received 33 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 69.05% of users gave Relay Therapeutics an outperform vote while only 56.82% of users gave 2seventy bio an outperform vote. CompanyUnderperformOutperform2seventy bioOutperform Votes2556.82% Underperform Votes1943.18% Relay TherapeuticsOutperform Votes5869.05% Underperform Votes2630.95% Do analysts recommend TSVT or RLAY? 2seventy bio presently has a consensus target price of $9.00, suggesting a potential upside of 180.37%. Relay Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 355.56%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relay Therapeutics is more favorable than 2seventy bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 2seventy bio 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56Relay Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Do insiders and institutionals hold more shares of TSVT or RLAY? 93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 7.2% of 2seventy bio shares are owned by insiders. Comparatively, 4.3% of Relay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to TSVT or RLAY? In the previous week, Relay Therapeutics had 10 more articles in the media than 2seventy bio. MarketBeat recorded 11 mentions for Relay Therapeutics and 1 mentions for 2seventy bio. 2seventy bio's average media sentiment score of 1.87 beat Relay Therapeutics' score of 0.66 indicating that 2seventy bio is being referred to more favorably in the media. Company Overall Sentiment 2seventy bio Very Positive Relay Therapeutics Positive SummaryRelay Therapeutics beats 2seventy bio on 11 of the 19 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSVT vs. The Competition Export to ExcelMetric2seventy bioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.60M$6.86B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-1.7310.75130.2217.53Price / Sales1.65287.791,246.14139.51Price / CashN/A56.6541.2337.95Price / Book0.645.394.884.92Net Income-$217.57M$152.04M$119.65M$225.78M7 Day Performance-13.94%-4.32%16.62%-1.56%1 Month Performance-4.46%2.80%16.34%6.68%1 Year Performance-7.23%17.30%35.38%22.48% 2seventy bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSVT2seventy bio2.9913 of 5 stars$3.11-3.1%$9.00+189.4%-14.2%$160.45M$100.39M-1.67440Negative NewsRLAYRelay Therapeutics2.3509 of 5 stars$4.72+2.4%$20.50+334.3%-55.6%$790.03M$25.55M0.00304PRTAProthena1.7805 of 5 stars$14.64+4.2%$61.86+322.5%-64.9%$787.78M$91.37M0.00173News CoverageCRGXCARGO Therapeutics1.8446 of 5 stars$17.11-7.4%$31.80+85.9%-18.7%$787.57MN/A0.00116CRONCronos Group2.3265 of 5 stars$2.06+1.0%$3.00+45.6%+1.0%$787.53M$111.23M-15.62356Short Interest ↓News CoveragePositive NewsEOLSEvolus3.9308 of 5 stars$12.26-3.2%$23.00+87.6%+18.5%$776.30M$202.09M0.00170RAPPRapport Therapeutics1.8417 of 5 stars$21.17+3.5%$35.00+65.3%N/A$774.40MN/A0.00N/APositive NewsESPREsperion Therapeutics3.9707 of 5 stars$3.82+9.8%$8.17+113.8%+35.2%$752.69M$116.33M-5.97240Analyst ForecastGap UpANABAnaptysBio2.406 of 5 stars$24.59-0.9%$54.64+122.2%-16.9%$748.27M$17.16M0.00100Short Interest ↑Analyst RevisionCGEMCullinan Therapeutics1.795 of 5 stars$12.84-1.7%$31.67+146.6%+39.4%$747.67M$18.94M-4.5330Short Interest ↑DNTHDianthus Therapeutics1.666 of 5 stars$24.92+2.2%$46.43+86.3%+235.7%$737.63M$2.83M0.0080Positive News Related Companies and Tools Related Companies Relay Therapeutics Competitors Prothena Competitors CARGO Therapeutics Competitors Cronos Group Competitors Evolus Competitors Rapport Therapeutics Competitors Esperion Therapeutics Competitors AnaptysBio Competitors Cullinan Therapeutics Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TSVT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TSVT Stock Alerts